Probiotic compositions and uses thereof

A technology of probiotics and compositions, applied in the field of probiotics strains

Pending Publication Date: 2021-03-30
PROBI AB LUND SE
View PDF17 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It has been reported that there is a significant protective effect on the cortical bone of ovariectomized mice, but not on the trabecular bone of ovariectomized mice. No

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Probiotic compositions and uses thereof
  • Probiotic compositions and uses thereof
  • Probiotic compositions and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example A

[0118] Example A: Tablet

[0119] Probiotic strains 1x10 9 CFU or preferably 1x10 10 CFU

[0120]

[0121] Tablets are prepared from the above ingredients by wet granulation followed by compression.

example B

[0122] Example B: Tablet Formulation

[0123] Formulations A and B below were prepared by wet granulating the ingredients with a solution of povidone, then adding magnesium stearate and by compression.

[0124] Formulation A

[0125]

[0126] (* = or preferably 1x10 10 CFU)

[0127] Formulation B

[0128]

[0129] (* = or preferably 1x10 10 CFU)

[0130] Formulation C

[0131]

[0132] Formulations D and E below were prepared by direct compression blending the ingredients. The lactose used in Formulation E is of the direction compression type.

[0133] Formulation D

[0134] Probiotic strains 1x10 9 CFU or preferably 1x10 10 CFU

[0135] Pregelatinized Starch NF15 150mg

[0136] Formulation E

[0137] Probiotic strains 1x10 9 CFU or preferably 1x10 10 CFU

[0138] Lactose 150mg

[0139] 100mg

[0140] Formulation F (controlled release formulation)

[0141] The formulation was prepared by wet granulating the ingredients (below) with a ...

example C

[0144] Example C: Capsule formulation

[0145] Formulation A

[0146] A capsule formulation was prepared by mixing the ingredients of Formulation D in Example B above and filling into two-section hard gelatin capsules. Formulation B (below) was prepared in a similar manner.

[0147] Formulation B

[0148]

[0149] Formulation C

[0150] (a) Probiotic strains 1x10 9 CFU or preferably 1x10 10 CFU

[0151] (b) Macrogol 4000BP 350mg

[0152] Capsules were prepared by: melting polyethylene glycol 4000BP; dispersing one or more probiotic strains in the melt; and filling the melt into two-section hard gelatin capsules.

[0153] Formulation D (controlled release capsule )

[0154] The following controlled release capsule formulation was prepared by extruding ingredients a, b and c using an extruder, then spheronizing the extrudate and drying. The dried granules were then coated with a release controlling film (d) and filled into two-part hard gelatin capsules.

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to at least one probiotic strain chosen from Lactobacillus paracasei 8700:2 (DSM 13434) and / or at least one probiotic strain of Lactobacillus piantarum, for use in the treatmentand / or prevention of trabecular bone loss, in a mammal, preferably in anon-rodent mammal, more preferably in a human, most preferably in a peri-menopausal woman, post-menopausal woman or a woman six years or less after onset of menopause.

Description

technical field [0001] The present invention relates to at least one probiotic bacterial strain selected from Lactobacillus paracasei 8700:2 (DSM 13434) and / or at least one probiotic bacterial strain of Lactobacillus plantarum for treating and / or preventing trabecular bone loss in mammals. Preferably, the use is for the treatment of a non-rodent mammal, more preferably a human, and most preferably a perimenopausal woman, a postmenopausal woman or a woman six years or less after menopause has occurred. Background technique [0002] Bone tissue is two types of mineralized tissue, cortical (also known as compact) bone and trabecular (also known as cancellous or spongy) bone. [0003] Cortical bone is denser and stronger than trabecular bone and forms the hard exterior (cortex) of the bone. Microscopically, human cortical bone consists of bony cylinders formed of concentric rings of calcified matrix, called lamellae, that surround a central (Havers) canal that includes blood ve...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/747A61P19/10
CPCA61K35/747A61P19/10A61K31/59C12N1/20C12R2001/225A61K31/593
Inventor C·S·A·奥尔松I·拉佐阿伦N·拉斯森
Owner PROBI AB LUND SE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap